Loading
A phase 2 trial of Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in non-Hodgkin lymphoma, run by Celgene, active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma is a phase 2 interventional study registered as NCT06425302 by Celgene, with 95 participants enrolled, started 2024-08-30 and due to reach its primary completion in 2026-06-19. Interventions recorded: Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Golcadomide, PROTACs & molecular glues (targeted protein degradation), Vincristine, Rituximab.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.